MDGLMadrigal Pharmaceuticals, Inc.

$10B

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$380M

Net Income

-$374M

EPS (Diluted)

$-19.99

Cash Flow

Operating Cash Flow

-$324M

Free Cash Flow

-$326M

Stock-Based Comp.

$50M

Balance Sheet

Total Assets

$641M

Total Liabilities

$235M

Stockholders' Equity

$405M

Cash & Equivalents

$100M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$380M	-$294M	-29.6%
Net Income	-$374M	-$295M	-26.5%

MDGL FY 2023 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena